{
    "clinical_study": {
        "@rank": "46780", 
        "arm_group": {
            "arm_group_label": "Laser Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Evaluation of the safety and efficacy of the 755nm Alex laser for the treatment of benign\n      pigmented and vascular lesions and scars"
        }, 
        "brief_title": "755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Benign Pigmented and Vascular Lesions and Scars", 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male or female subjects between 18 and 85 years of age.\n\n          2. Subjects with Fitzpatrick skin types I to VI.\n\n          3. Subjects who have unwanted pigmented lesions, vascular lesions, striae and/or\n             hypertrophic or atrophic scars\n\n          4. Subject who are willing to consent to participate in the study.\n\n        4.2 Exclusion Criteria\n\n          1. Subject who will not be photographed or who will not cooperate with the post\n             treatment care and follow up schedule\n\n          2. Hypersensitive to light exposure.\n\n          3. Active localized or systemic infections.\n\n          4. Taking medication for which sunlight is a contraindication.\n\n          5. History of squamous cell carcinoma or melanoma.\n\n          6. History of keloid scarring.\n\n          7. Use of oral isotretinoin (Accutane\u00ae) within 12 months of initial treatment or during\n             the course of the study. Note: Skin must regain its normal degree of moisture prior\n             to treatment.\n\n          8. Prior treatment with laser or other devices in treatment area within 3 months\n\n          9. History of immunosuppression/immune deficiency disorders (including HIV infection or\n             AIDS) or use of immunosuppressive medications.\n\n         10. Subjects who are pregnant, have been pregnant within the last 3 months, are currently\n             breast feeding or are planning a pregnancy within the study period.\n\n         11. Subjects that the physician determines ineligible based on standard of care\n             treatment.\n\n             -\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745627", 
            "org_study_id": "CYN11-PICO_RG2_PL"
        }, 
        "intervention": {
            "arm_group_label": "Laser Treatment", 
            "intervention_name": "755nm Alex laser", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "Laser & Skin Surgery Center of New York"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluate aesthetic improvement based on photographic scale", 
            "safety_issue": "No", 
            "time_frame": "1 and 3 months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Histology based on tissue biopsy", 
            "safety_issue": "Yes", 
            "time_frame": "3 months post last treatment"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}